Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum (Q27851722)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum	scientific article

Statements

scholarly article

1 reference

13 November 2016

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum (English)

1 reference

13 November 2016

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

D H Yoon

1

0 references

M-H Ryu

2

0 references

Y S Park

3

0 references

H J Lee

4

0 references

C Lee

5

0 references

B-Y Ryoo

6

0 references

J-L Lee

7

0 references

H-M Chang

8

0 references

T W Kim

9

0 references

Y-K Kang

10

0 references

language of work or name

0 references

publication date

13 March 2012

0 references

British Journal of Cancer

1 reference

106

0 references

1039-44

0 references

6

0 references

Global cancer statistics, 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

20 March 2017

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

7 April 2017

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

7 April 2017

The TOR pathway: a target for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

7 April 2017

The mTOR pathway: a new target in cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

29 September 2017

Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

29 September 2017

Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

29 September 2017

Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304416

29 September 2017

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.47

21 January 2018

Mechanism and management of AKT inhibitor-induced hyperglycemia

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.47

21 January 2018

Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.47

21 January 2018

The prevalence of PIK3CA mutations in gastric and colon cancer.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.47

21 January 2018

Phosphatase Protein Homologue to Tensin Expression and Phosphatidylinositol-3 Phosphate Kinase Mutations in Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.47

21 January 2018

Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22343617

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22343617

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2012.47

0 references

Dimensions Publication ID

0 references

1 reference

13 November 2016

1 reference

13 November 2016

ResearchGate publication ID

0 references

Springer Nature article ID

10.1038/bjc.2012.47

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27851722&oldid=1951401599"